Transcription
Hi, I'm Derek Mueller, PA from Detroit, Michigan, and I'm recording here from ACR Convergence 2026 in Orlando, Florida. And today I'm here to talk to you about something that we all get a little freaked out about, and that's myositis and the mortality risk.
So I'm here to talk to you about abstract number 0645. And this was looking at newly diagnosed myositis patients who have associated interstitial lung disease. This was a cohort of 41 newly diagnosed myositis-associated patients, specifically looking at the 2-year mortality as well as lung transplant risk of these patients over time.
This population included a median age of 57-year-old patients, majority female. And this was also a pretty sick population. 44% of these patients were on supplemental oxygen at time of enrollment into the study, and 14% of patients were hospitalized at the beginning of this study period as well.
So over the 2-year period of observation, 15% of these patients unfortunately died, and the average time at which these patients passed was at 8 and a half months. 10% of these patients were transplanted — lung transplant — and this occurred around 13 months. Of the survivors in this group, only 13% of patients did progress, and 47% actually did see an improvement, and that was by an equal or greater than 10% improvement in predicted FVC.
These improvements in the patients who are the survivors — they actually improved regardless of whether they were on supplemental oxygen at baseline.
So I think some key takeaways here is that interstitial lung disease in myositis is front-loaded. The severity seems to be the most at the beginning of the course. And this is something where, with proper and aggressive treatment, these are patients who can survive and thrive and they can improve over time.
So I'm here to talk to you about abstract number 0645. And this was looking at newly diagnosed myositis patients who have associated interstitial lung disease. This was a cohort of 41 newly diagnosed myositis-associated patients, specifically looking at the 2-year mortality as well as lung transplant risk of these patients over time.
This population included a median age of 57-year-old patients, majority female. And this was also a pretty sick population. 44% of these patients were on supplemental oxygen at time of enrollment into the study, and 14% of patients were hospitalized at the beginning of this study period as well.
So over the 2-year period of observation, 15% of these patients unfortunately died, and the average time at which these patients passed was at 8 and a half months. 10% of these patients were transplanted — lung transplant — and this occurred around 13 months. Of the survivors in this group, only 13% of patients did progress, and 47% actually did see an improvement, and that was by an equal or greater than 10% improvement in predicted FVC.
These improvements in the patients who are the survivors — they actually improved regardless of whether they were on supplemental oxygen at baseline.
So I think some key takeaways here is that interstitial lung disease in myositis is front-loaded. The severity seems to be the most at the beginning of the course. And this is something where, with proper and aggressive treatment, these are patients who can survive and thrive and they can improve over time.
Recommended videos
-
Rheumatoid Arthritis
RNL 26 Report: RA-ILD
-
Education/ACR/EULAR
ILD in Sjögren's and Beyond: ACR vs EULAR Guidelines
-
Rheumatoid Arthritis
RNL 26 Report: Rheumatoid Arthritis

If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.